Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Tirzepatide-based medicines Mounjaro for diabetes and Zepbound for obesity have led the ... Shares in the company rose nearly 9.5% after the results were announced. The strong growth for Lilly's ...

In the 176-week study run over three years – which underpinned tirzepatide's approval for obesity last year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg ...

Microdosing GLP-1 has been touted for everything for weight management to perimenopause symptoms. But is it all it’s cracked ...

Increasing the Dose: After four weeks, the dose may be increased to 0.5 mg. Depending on your response and tolerance ... as well as other weight loss medications such as Zepbound and Mounjaro. While ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...